Wolverine Stack: BPC-157 + TB-500 for Healing

The Wolverine Stack pairs BPC-157 with TB-500 for soft-tissue and tendon recovery. The mechanism rationale: two complementary healing pathways — angiogenesis and tissue migration — that hit different limiting steps in the repair cascade. The combination is the most-commonly-cited research-use stack for acute injury and post-surgical recovery, though direct head-to-head data testing additive vs single-peptide outcomes does not exist. This article covers the rationale, a representative dosing pattern, the evidence frame, and how to run the cycle.

For the per-peptide comparison, see BPC-157 vs TB-500. For per-peptide profiles, see BPC-157 and TB-500.

Why the stack exists

Soft-tissue healing — tendon repair, ligament recovery, muscle tear, post-surgical wound — depends on multiple parallel cellular processes:

1. Angiogenesis — new blood vessels grow into the injured area to supply oxygen and nutrients.
2. Cell migration — fibroblasts, endothelial cells, and stem cells navigate to the wound site.
3. Collagen synthesis — building new connective-tissue scaffold.
4. Inflammation modulation — moving through the inflammatory phase without getting stuck in it.

BPC-157 primarily targets angiogenesis and collagen synthesis — the building and connecting side. It upregulates VEGF, modulates the nitric-oxide pathway, and directly stimulates tendon-fibroblast outgrowth in cell culture.

TB-500 primarily targets cell migration — the getting cells to the right place side. It sequesters G-actin, allowing the cytoskeletal rearrangement that lets cells navigate to wound sites. It also drives angiogenesis through a partially independent pathway.

The mechanisms overlap (both drive angiogenesis) but don't duplicate. The hypothesis is that the two peptides hit different limiting steps in the healing cascade, and the combination produces additive effects.

This is mechanistically plausible. It is not directly proven — no published Phase 2 or Phase 3 trial has compared the stack vs either monotherapy in humans.

What goal the stack is for

The stack is most-cited for:

• Acute tendon and ligament injury. Achilles, rotator cuff, patellar, plantar fascia, ACL/MCL recovery.
• Acute muscle strain or tear.
• Post-surgical recovery. Especially orthopedic procedures. Always discuss with the surgical team — peptide effects on surgical-site biology aren't well-characterized clinically.
• Chronic tendinopathy that hasn't responded to standard care.
• Joint pain from cumulative wear or training overuse.

It is not a daily-driver longevity stack, an anti-aging stack, or a body-composition stack. It's an acute or sub-acute injury intervention.

A representative dosing pattern

The most-commonly-cited research-use pattern:

BPC-157:

• 250 mcg twice daily.
• Subcutaneous, rotating injection sites.
• For acute injury: ideally near the injury site if accessible (e.g., subcutaneous abdominal dose for GI healing, near-site subcutaneous for accessible tendon work).
• Duration: 4–6 weeks.

TB-500:

• Loading: 2–2.5 mg twice weekly for the first 4 weeks.
• Maintenance: 2–2.5 mg once weekly for an additional 4 weeks.
• Subcutaneous, any site (TB-500 distributes systemically — site is less critical than for BPC-157).

Total stack cycle: 4–8 weeks active dosing, then a 4-week washout to reassess.

For reconstitution math, use the calculator. Typical reconstitutions:

• BPC-157 5 mg vial + 2 mL BAC water = 2.5 mg/mL → 250 mcg = 10 units on a U-100 syringe.
• TB-500 5 mg vial + 1 mL BAC water = 5 mg/mL → 2.5 mg = 50 units on a U-100 syringe (use a 1 mL barrel).

Some users prefer to mix the two compounds in separate syringes and inject at separate sites. Others combine them in a single syringe immediately before injection. Both are practiced; the published research uses separate administration.

For technique see how to inject peptides and where to inject peptides.

Optional third addition: GHK-Cu

Some practitioners add GHK-Cu (1–2 mg, 2–3× weekly subcutaneous) to the stack, particularly for skin or surgical-incision healing. The rationale: copper-peptide-driven dermal regeneration on top of the tendon/muscle effects of BPC-157 and TB-500.

This adds another moving part and another side-effect surface; only add if the indication specifically benefits (visible scar tissue, dermal involvement, etc.).

GHK-Cu. Copper peptides guide.

What to expect

A realistic timeline:

• Weeks 1–2: Subtle change. Some users report reduced inflammation or pain by week 2. Don't expect dramatic visible improvement yet.
• Weeks 3–4: More noticeable effect. Tendon-quality changes (movement range, pain on load) tend to show by week 3 or 4 for moderate-severity injuries.
• Weeks 5–8: The bulk of the visible benefit. By the end of cycle most users report meaningful improvement in the targeted injury.
• Post-washout: Reassess. If improvement plateaued or reversed, consider a second cycle.

These are not guaranteed responses — peptide healing is real but variable. About 60–80% of users with acute soft-tissue injuries report meaningful benefit in community data, with the rest reporting minimal or no effect.

Side effects

The Wolverine Stack has a favorable acute-safety profile in the published research. Common patterns:

• Mild injection-site irritation — usually a site-rotation issue.
• Transient lightheadedness in the first few doses, particularly with BPC-157.
• Mild fatigue at higher TB-500 doses.

Allergic reactions are rare but possible. Long-term chronic-dose safety in humans is unstudied for both peptides — this is the primary reason for the structured cycling pattern rather than continuous dosing.

See are peptides safe? and peptide side effects for the full safety frame.

Cycle structure

A complete cycle template:

Week	BPC-157	TB-500	Notes
Week 0 (baseline)	—	—	Photo + functional assessment of injury
Weeks 1–4 (loading)	250 mcg BID daily	2.5 mg twice weekly	Loading phase
Weeks 5–8 (maintenance)	250 mcg BID daily	2.5 mg once weekly	Maintenance phase
Weeks 9–12 (washout)	—	—	Reassess at week 12

A shorter 4-week cycle is reasonable for less severe injuries; cycles longer than 8 weeks on are less commonly recommended given the limited long-term safety data.

Stacking with other peptides

Reasonable additions for specific indications:

• GHK-Cu for scar tissue / dermal involvement (above).
• CJC-1295 + Ipamorelin for general recovery support during a heavy training phase, but this is a different goal layer rather than a healing additive.
• Tesamorelin or HGH for older users with documented GH deficiency.

Not recommended:

• Adding a second healing peptide (LL-37, Thymosin Alpha-1, KPV) without a specific reason — mechanism overlap, no published evidence for additive effect.
• Stacking with anti-inflammatory drugs in high doses (NSAIDs in particular) — inflammation is part of the healing process, and chronic NSAID use may blunt the healing-peptide effect.

When the stack isn't the right tool

• Chronic systemic conditions. Autoimmune disease, chronic regional pain syndrome, fibromyalgia — none of these have specific evidence for the Wolverine Stack.
• Acute infection. Don't dose into an active infectious process. Treat infection first.
• Active cancer or cancer history without oncology sign-off. Angiogenesis-driving compounds and cancer are a known concern.
• Pre-surgery, very close to surgery date. Some surgeons specifically ask patients to stop research peptides 2–4 weeks before procedures. Ask.

Where to go from here

• Per-peptide profiles: BPC-157, TB-500, GHK-Cu.
• BPC-157 vs TB-500 — head-to-head comparison.
• /peptides/category/healing and /peptides/category/joint-pain — the hubs.
• Operational guides: calculator, how to reconstitute, how to inject, peptide cycling.
• Safety: are peptides safe?, peptide side effects.